Epigenetic Perturbations by Arg882-Mutated DNMT3A Potentiate Aberrant Stem Cell Gene-Expression Program and Acute Leukemia Development
Open accessThe DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
SUMMARY DNA methyltransferase 3A (DNMT3A) is frequently mutated in hematological cancers; however, the underlying oncogenic mechanism remains elusive. Here, we report that DNMT3A mutational hotspot at Arg882 (DNMT3AR882H) cooperates with NRAS mutation to transform hematopoietic stem/progenitor cells and induce acute leukemia development. Mechanistically, DNMT3AR882H directly binds to and potentiates transactivation of stemness genes critical for leukemogenicity including Meis1, Mn1 and Hoxa gene cluster. DNMT3AR882H induces focal epigenetic alterations, including CpG hypomethylation and concurrent gain of active histone modifications, at cis-regulatory elements such as enhancers to facilitate gene transcription. CRISPR/Cas9-mediated ablation of a putative Meis1 enhancer carrying DNMT3AR882H-induced DNA hypomethylation impairs Meis1 expression. Importantly, DNMT3AR882H-induced gene expression programs can be repressed through Dot1l inhibition, providing an attractive therapeutic strategy for DNMT3A-mutated leukemias.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Functions of DNA methylation: islands, start sites, gene bodies and beyond
Jones, P. A. (2012) · Nature Reviews Genetics · doi:10.1038/nrg3230 · Cited by 6,061
Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia
The Cancer Genome Atlas Research Network (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1301689 · Cited by 5,078
Age-related clonal hematopoiesis associated with adverse outcomes
Jaiswal, S., Fontanillas, P., Flannick, J., Manning, A., Grauman, P. V., Mar, B. G., Lindsley, R. C., Mermel, C. H., Burtt, N., Chavez, A., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1408617 · Cited by 4,841 · cited 4×
“derived hematopoiesis at premalignant stages (Genovese et al., 2014; Jaiswal et al., 2014; Shlush et al., 2014; Xie et al., 2014) and often coexist with a secondary lesion that ‘‘hits’’ either the FLT3RAS kinase pathway, an epigenetic regulator (IDH1/2, TET2), or NPM1 in AML patients (Cancer Genome Atlas Research Netw…”
InfluentialCellular senescence: when bad things happen to good cells
Campisi, J., & d'Adda di Fagagna, F. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2233 · Cited by 4,441
Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence
Genovese, G., Kähler, A. K., Handsaker, R. E., Lindberg, J., Rose, S. A., Bakhoum, S. F., Chambert, K., Mick, E., Neale, B. M., Fromer, M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1409405 · Cited by 3,531
A unique chromatin signature uncovers early developmental enhancers in humans
Rada-Iglesias, A., Bajpai, R., Swigut, T., Brugmann, S. A., Flynn, R. A., & Wysocka, J. (2011) · Nature · doi:10.1038/nature09692 · Cited by 2,233
Function and information content of DNA methylation
Schübeler, D. (2015) · Nature · doi:10.1038/nature14192 · Cited by 2,060 · cited 2×
“DNA methylation provides a critical epigenetic means for defining cellular identity and regulating functional output of gene-regulatory elements such as promoters and enhancers (Jones, 2012; Schubeler, 2015).”
DNMT3A Mutations in Acute Myeloid Leukemia
Ley, T. J., Ding, L., Walter, M. J., McLellan, M. D., Lamprecht, T., Larson, D. E., Kandoth, C., Payton, J. E., Baty, J., Welch, J., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1005143 · Cited by 1,983
Age-related mutations associated with clonal hematopoietic expansion and malignancies
Xie, M., Lu, C., Wang, J., McLellan, M. D., Johnson, K. J., Wendl, M. C., McMichael, J. F., Schmidt, H. K., Yellapantula, V., Miller, C. A., et al. (2014) · Nature Medicine · doi:10.1038/nm.3733 · Cited by 1,874
Transformation from committed progenitor to leukaemia stem cell initiated by MLL–AF9
Krivtsov, A. V., Twomey, D., Feng, Z., Stubbs, M. C., Wang, Y., Faber, J., Levine, J. E., Wang, J., Hahn, W. C., Gilliland, D. G., et al. (2006) · Nature · doi:10.1038/nature04980 · Cited by 1,513 · cited 2×
“First, we asked whether they carry self-renewal or stemness gene-expression programs, a known feature of LSCs (Abramovich et al., 2005; Eppert et al., 2011; Krivtsov et al., 2006).”
Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia
Shlush, L. I., Zandi, S., Mitchell, A., Chen, W. C., Brandwein, J. M., Gupta, V., Kennedy, J. A., Schimmer, A. D., Schuh, A. C., Yee, K. W., et al. (2014) · Nature · doi:10.1038/nature13038 · Cited by 1,443
Self-citationChromatin state dynamics during blood formation
Lara-Astiaso, D., Weiner, A., Lorenzo-Vivas, E., Zaretsky, I., Jaitin, D. A., David, E., Keren-Shaul, H., Mildner, A., Winter, D., Jung, S., et al. (2014) · Science · doi:10.1126/science.1256271 · Cited by 776
Hox genes in hematopoiesis and leukemogenesis
Argiropoulos, B., & Humphries, R. K. (2007) · Oncogene · doi:10.1038/sj.onc.1210760 · Cited by 492 · cited 2×
“12 Cancer Cell 30, 1–16, July 11, 2016 circuitry is crucial for both normal expansion of HSCs and malignant transformation of LSCs (Argiropoulos and Humphries, 2007; Heuser et al., 2011), deregulation of this TF node by R882-mutated DNMT3A provides a molecular explanation not only for malignant hematopoiesis but also…”
Russler-Germain, D. A., Spencer, D. H., Young, M. A., Lamprecht, T. L., Miller, C. A., Fulton, R., Meyer, M. R., Erdmann-Gilmore, P., Townsend, R. R., Wilson, R. K., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.02.010 · Cited by 452 · cited 10×
“Clinical evidence supports this notion as AML patients with DNMT3A R882 mutation exhibited focal DNA hypomethylation (Russler-Germain et al., 2014).”
InfluentialStructural insight into autoinhibition and histone H3-induced activation of DNMT3A
Guo, X., Wang, L., Li, J., Ding, Z., Xiao, J., Yin, X., He, S., Shi, P., Dong, L., Li, G., et al. (2015) · Nature · doi:10.1038/nature13899 · Cited by 361 · cited 2×
“DNMT3A R882H binding regions also showed depletion of H3K4me3 (Figure 4D), a histone modification known to suppress DNMT3A binding due to an intrinsic histone H3 ‘‘reader’’ activity of DNMT3A’s ADD domain (Guo et al., 2015; Noh et al., 2015).”
Shih, A. H., Jiang, Y., Meydan, C., Shank, K., Pandey, S., Barreyro, L., Antony-Debre, I., Viale, A., Socci, N., Sun, Y., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.03.009 · Cited by 236 · cited 2×
“For example, despite a large number of DMCs found associated with either DNMT3A or TET2 mutation in AML, a relatively small number of genes show changes in their expression (Russler-Germain et al., 2014; Shih et al., 2015).”
A DNMT3A mutation common in AML exhibits dominant-negative effects in murine ES cells
Kim, S. J., Zhao, H., Hardikar, S., Singh, A. K., Goodell, M. A., & Chen, T. (2013) · Blood · doi:10.1182/blood-2013-02-483487 · Cited by 180 · cited 4×
“Due to a primarily heterozygous nature of DNMT3A R882 mutation, it was thought to act in a dominant-negative and/or haploinsufficient manner (Holz-Schie-tinger et al., 2012; Kim et al., 2013; Russler-Germain et al., 2014).”
InfluentialCelik, H., Mallaney, C., Kothari, A., Ostrander, E. L., Eultgen, E., Martens, A., Miller, C. A., Hundal, J., Klco, J. M., & Challen, G. A. (2015) · Blood · doi:10.1182/blood-2014-08-594564 · Cited by 95 · cited 2×
“Mice with Dnmt3a mutation alone did not develop frank AML but showed increased susceptibility to malignant development upon acquisition of additional mutations (Celik et al., 2015; Chang et al., 2015; Mayle et al., 2015; Xu et al., 2014).”
Cited by
Epigenetic plasticity and the hallmarks of cancer
Flavahan, W. A., Gaskell, E., & Bernstein, B. E. (2017) · Science · doi:10.1126/science.aal2380 · Cited by 1,340
“DNA methyltransferase mutations can lead to hypomethylation and aberrant activation of enhancers that drive leukemogenic gene expression patterns (68, 69).”
BackgroundIntra-tumor heterogeneity from a cancer stem cell perspective
Prasetyanti, P. R., & Medema, J. P. (2017) · Molecular Cancer · doi:10.1186/s12943-017-0600-4 · Cited by 800
Phase separation drives aberrant chromatin looping and cancer development
Ahn, J. H., Davis, E. S., Daugird, T. A., Zhao, S., Quiroga, I. Y., Uryu, H., Li, J., Storey, A. J., Tsai, Y.-H., Keeley, D. P., et al. (2021) · Nature · doi:10.1038/s41586-021-03662-5 · Cited by 457
Self-citationThe language of chromatin modification in human cancers
Zhao, S., Allis, C. D., & Wang, G. G. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-021-00357-x · Cited by 402
Self-citationTumor initiation and early tumorigenesis: molecular mechanisms and interventional targets
Zhang, S., Xiao, X., Yi, Y., Wang, X., Zhu, L., Shen, Y., Lin, D., & Wu, C. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01848-7 · Cited by 399
Metadata
- Authors
- Lu, R., Wang, P., Parton, T., Zhou, Y., Chrysovergis, K., Rockowitz, S., Chen, W.-Y., Abdel-Wahab, O., Wade, P. A., Zheng, D., & Wang, G. G.
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2016-07
- Volume
- 30
- Issue
- 1
- Pages
- 92-107
- ISSN
- 1535-6108 (ISSN-L)
- OpenAlex
- W2472017314
- Cited by
- 156
- References
- 18
- FWCI
- 16.59
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.